SCNLF (Scancell Holdings) 6-Month Price Index: 0.67 (As of Aug. 28, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SCNLF Scancell Holdings PLC SCNLF
18 GF Score
Price $0.13
! 1 Warning Sign
View Full Analysis

What is Scancell Holdings 6-Month Price Index?

Scancell Holdings SCNLF -0.22% 18 6-Month Price Index is 0.67 as of Aug. 28, 2026. GuruFocus rates SCNLF with a GF Score™ of 18/100. The stock has 1 warning sign investors should review.

6-Month Price Index is an intermediate-term momentum that shows the price change relative to 6-month ago. It’s calculated by current share price divided by share price 6-months ago. As of today (2026-08-28), Scancell Holdings's 6-Month Price Index is 0.67.

Scancell Holdings  (OTCPK:SCNLF) 6-Month Price Index Explanation

Price Index (PI) also called momentum. Strategies involving Price Index are also known as momentum strategies as they allow investors to profit from a company’s stock price. 6-Month Price Index is an intermediate-term momentum that shows the price change relative to 6-month ago.

The investment strategy for momentum investors is to buy winners and sell losers. That is, buy stocks that performed well and sell stocks that performed poorly in the past.

Scancell Holdings 6-Month Price Index Related Terms

SCNLF vs VRTX, REGN, RVMD: 6-Month Price Index Comparison

For the Biotechnology subindustry, Scancell Holdings's 6-Month Price Index, along with its competitors' market caps and 6-Month Price Index data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

SCNLF
18GF Score
Scancell Holdings PLC SCNLF
6-Month Price Index is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Scancell Holdings  (OTCPK:SCNLF) 6-Month Price Index Calculation

6-Month Price Index is calculated as following:

6-Month Price Index=Current Share Price / Share Price 6-Months Ago

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about 6-Month Price Index →
What does a 6-Month Price Index of 0.67 mean?
Scancell Holdings (SCNLF) has a 6-Month Price Index of 0.67 as of Aug. 28, 2026. 6-Month Price Index is an intermediate-term momentum that shows the price change relative to 6-month ago. View historical data on Scancell Holdings and its competitors.
Is Scancell Holdings' 6-Month Price Index too high?
Scancell Holdings' current 6-Month Price Index is 0.67. Overall, Scancell Holdings has a GF Score™ of 18/100, reflecting its overall financial health beyond just this single metric.
How does Scancell Holdings' 6-Month Price Index compare to VRTX and REGN?
Scancell Holdings' 6-Month Price Index of 0.67 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 6-Month Price Index for a Biotechnology company?
A good 6-Month Price Index depends on the Biotechnology industry context. However, 6-Month Price Index should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 6-Month Price Index mean?
A high 6-Month Price Index can signal that a stock is expensive relative to its fundamentals. 6-Month Price Index is an intermediate-term momentum that shows the price change relative to 6-month ago. View historical data on Scancell Holdings and its competitors. Scancell Holdings's current 6-Month Price Index is 0.67. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Scancell Holdings stock overvalued right now?
Scancell Holdings (SCNLF) has a current 6-Month Price Index of 0.67. The current 6-Month Price Index is 0.67. Scancell Holdings' overall GF Score™ is 18/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 6-Month Price Index calculated?
6-Month Price Index is calculated from a company's financial statements. For Scancell Holdings (SCNLF), the current 6-Month Price Index is 0.67 as of Aug. 28, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Scancell Holdings Business Description

Other Exchanges SCLP:UKSCP:Germany
Address Sanders Road, Unit 202, Bellhouse Building, Oxford Science Park, Oxford, GBR, OX4 4GD
Scancell Holdings PLC is a clinical-stage biotechnology company developing targeted off-the-shelf active immunotherapies to generate safe and long-lasting tumour-specific immunity for a cancer-free future. iSCIB1+, a product from its DNA ImmunoBody platform (AvidiMab), has demonstrated safe, durable, and clinically meaningful benefit as a monotherapy as well as additional benefit when combined with checkpoint therapies in an ongoing Phase 2 trial in melanoma. Modi-1, the peptide immunotherapy from its Moditope platform, is being investigated in a Phase 2 study in a broad range of solid tumours. In addition, the company has established a subsidiary with the intention to hold and develop an early-stage pipeline of high-affinity GlyMab antibodies targeting tumour-specific glycans.
18GF Score

Get the complete analysis for SCNLF

6-Month Price Index is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.13
Price